Bristol-Myers Squibb Company recalls Opdualag (nivolumab and relatlimab-rmbw) injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Lack of Assurance of Sterility.
- Products
-
- Opdualag (nivolumab and relatlimab-rmbw) injection
- Company
- Bristol-Myers Squibb Company
- Where it was sold
-
Nationwide in the USA
Nationwide
- Units affected
- 12,778 total vials
- About this recall
- Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11